Patients
Cemi, PTCL, DLBCL, cHL, ≥15,000/mmExposure, leukocytosis
ALEUKOCYTOSIS, S; HEMOGLOBIN, CHL
In cohorts A1, A2, B, and C, 18, 12, 17, and 11 patients were enrolled, respectively. Patient baseline characteristics are shown in Table Patient baseline characteristics
Abbreviations: Different risk factors are used to calculate the International Prognostic Score for cHL, DLBCL, and PTCL. For cHL cohorts, 1 point is added with the presence of each of the following criteria: age ≥45 years; albumin <4 g/dl; hemoglobin <10.5 g/dl; leukocytosis (white blood cell count ≥15,000/mmExposure to Isa + Cemi was longer in the cHL cohorts compared with the DLBCL and PTCL cohorts. Median (range) duration of exposure and number of cycles, respectively were 33.0 (6–69) weeks and 8.5 (1–21) in the cHL anti‐PD‐1/PD‐L1 naïve cohort, 36.1 (4–83) weeks and 10.0 (1–25) in the cHL anti‐PD‐1/PD‐L1 progressors cohort, 4.0 (2–41) weeks and 1.0 (1–11) in the DLBCL cohort, and 4.1 (2–38) weeks and 1.0 (1–10) in the PTCL cohort.